<DOC>
	<DOCNO>NCT02921126</DOCNO>
	<brief_summary>To quantify rate bleed event investigate characteristic prescribed patient , rate bleed event , persistence healthcare resource utilization Oral Anticoagulants ( OACs ) prescribe routine clinical practice .</brief_summary>
	<brief_title>Real-World Evidence Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>least 18 year age index date Initiated new OAC therapy ( previous prescription index OAC last 12 month prior index date ) study period Had least 1 claim diagnosis AF anytime record Have record indicative Valvular Atrial Fibrillation period Have history OACs prescribe study period assess period data availability ( i.e . history index OAC , patient need newly prescribe either apixaban , rivaroxaban , dabigatran VKA ) Have one OAC exposure start date</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>